Publication:
Determination of CYP2C19 Polymorphism, Side Effects, and Medication Adherence in Patients Who have Utilized Selective Serotonin Reuptake Inhibitors

dc.contributor.authorDeniz, Semanur
dc.contributor.authorSANCAR, MESUT
dc.contributor.authorOKUYAN, BETÜL
dc.contributor.authorATA, PINAR
dc.contributor.authorOzakpinar, Ozlem Bingol
dc.contributor.authorTALAS, Anil
dc.contributor.authorGUNES, Tufan
dc.contributor.authorCALISKAN, Mecit
dc.contributor.authorIzzettin, Fikret Vehbi
dc.contributor.institutionauthorİZZETTİN, FIKRET VEHBI
dc.date.accessioned2020-10-29T17:22:16Z
dc.date.available2020-10-29T17:22:16Z
dc.date.issued2016-06-01T00:00:00Z
dc.description.abstractObjective: The aim of this study is to determine relationship of cytochrome P-450 2C19 (CYP2C19) enzymes polymorphism, side effects, and medication adherence in patients who have been diagnosed with major depression and have utilized selective serotonin reuptake inhibitors.
dc.identifier.citationDeniz S., SANCAR M., OKUYAN B., ATA P., Ozakpinar O. B. , TALAS A., GUNES T., CALISKAN M., Izzettin F. V. , -Determination of CYP2C19 Polymorphism, Side Effects, and Medication Adherence in Patients Who have Utilized Selective Serotonin Reuptake Inhibitors-, KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, cilt.26, ss.152-160, 2016
dc.identifier.doi10.5455/bcp.20151003060610
dc.identifier.scopus84975520024
dc.identifier.urihttp://hdl.handle.net/20.500.12645/25695
dc.identifier.wosWOS:000383390400008
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleDetermination of CYP2C19 Polymorphism, Side Effects, and Medication Adherence in Patients Who have Utilized Selective Serotonin Reuptake Inhibitors
dc.typeArticle
dspace.entity.typePublication
local.avesis.id3f7b399c-15fa-46eb-a50f-0483248622f7
local.indexed.atWOS
local.indexed.atScopus
local.publication.isinternational1
relation.isAuthorOfPublicationcc4fb95b-daac-4065-9eea-9b57f6b44654
relation.isAuthorOfPublication.latestForDiscoverycc4fb95b-daac-4065-9eea-9b57f6b44654

Files